Sign up USA
Proactive Investors - Run By Investors For Investors

GenVec plunges as Novartis pauses clinical trial enrollment for CGF166

Novartis notifies the clinical-stage company it will conduct a safety review of patient data.
GenVec plunges as Novartis pauses clinical trial enrollment for CGF166
GenVec addresses therapeutic areas, such as hearing loss.

GenVec (NASDAQ:GNVC) plunged in morning trades after the clinical-stage biopharmaceutical company unveiled a setback in the study of CGF166, the company’s drug designed to help patients with bilateral severe-to-profound hearing loss.

Shares fell 62% to $0.650 at 11:04 a.m. in New York.

Novartis notified the Gaithersburg, Maryland-based company that it was pausing enrollment in the clinical trial of CGF166 to conduct a safety review of patient data, based on the recommendation of the trial’s data safety monitoring board, GenVec said.

“The trial will continue to collect new safety and efficacy data on patients currently enrolled in the study,” GenVec said.

The stock has lost four-fifths of its value over the past 12 months.

Register here to be notified of future GNVC Company articles
View full GNVC profile

Genvec Timeline

September 25 2012

Related Articles

March 31 2016
Amryt Pharmaceuticals is coming to the market following a reverse takeover deal with the investment firm Fastnet Equities. Here boss Joseph Wiley tells us a little bit more about the AIM newcomer.
April 13 2016
Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects of dissolving tablets and injections.
Copyright ©, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC